Lactobacillus plantarum CAU1055 ameliorates inflammation in lipopolysaccharide-induced RAW264.7 cells and a dextran sulfate sodium–induced colitis animal model

Abstract

This study aimed to screen lactic acid bacteria (LAB) for their anti-inflammatory activity by using RAW264.7 cells and dextran sulfate sodium (DSS)-induced colitis. In all, 192 LAB strains were isolated from healthy human feces, of which 8 strains showed excellent nitric oxide (NO) inhibitory activity. Peptidoglycan extracts of these 8 LAB strains were subjected to NO assay, Western blot, and ELISA. Among the 8 tested strains, extracts of 4 strains significantly inhibited the production of NO, related enzyme activities such as inducible nitric oxide synthase and cyclooxygenase 2, and key cytokines such as tumor necrosis factor-α and IL-6 in RAW264.7 cells. The 4 strains belonged to Lactobacillus (CAU1054, CAU1055, CAU1064, and CAU1301). Oral administration of the 4 strains inhibited DSS-induced body weight loss, colon shortening, and colon damage in ICR mice. The colon tissue of the mice treated with Lactobacillus plantarum strain CAU1055 had significantly reduced levels of inducible nitric oxide synthase, cyclooxygenase 2, tumor necrosis factor-α, and IL-6. We found that strain CAU1055 could be used as a candidate probiotic strain for the prevention and treatment of inflammatory bowel disease. Further studies are warranted to confirm the mechanisms of interaction between peptidoglycan of L. plantarum strain CAU1055 and upstream cellular signaling mediators.

Consortium of Probiotics Attenuates Colonization of Clostridioides difficile

“…Some probiotics have the property of decreasing inflammatory factors. Lactobacillus plantarum CAU1055 had significantly reduced levels of TNF-α, and IL-6 in a dextran sulfate sodiuminduced colitis animal model (Choi et al, 2019). Bifidobacterium animalis MB5 and Lactobacillus rhamnosus GG prevented the Escherichia coli-induced increased expression of IL-1β and TNF-α in Caco-2 cells (Roselli et al, 2006).…”

Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health

“…For instance, Lactobacillus casei PG was able to induce the production of IL-12 by mice peritoneal macrophages through toll-like receptors 2 (TLR2) and nucleotide-binding oligomerization domain 2 (NOD2) [ 192 ]. Moreover, L. plantarum CAU1055 PG demonstrated the ability to ameliorate nitric oxide-induced inflammation in RAW264.7 murine macrophages through the inhibition of nitric oxide (NO) synthase, cyclooxygenase-2 (COX-2), and cytokines (TNF-α and interleukin-6) [ 193 ]. In a similar study, PG derived from L. acidophilus has been reported to significantly reduce the NO synthase and COX-2 levels on LPS-induced RAW 264.7 macrophages as well [ 194 ].…”

Lactobacillus plantarum L15 Alleviates Colitis by Inhibiting LPS-Mediated NF-κB Activation and Ameliorates DSS-Induced Gut Microbiota Dysbiosis

“…A number of studies involving different L. plantarum strains have demonstrated in vitro and in vivo beneficial effects in UC therapy through normalizing disease activity index (DAI) score, significantly suppressing the expression of pro-inflammatory factors (TNF-α and IL-6), modulating gut microbiota, halting intestinal cell apoptosis as well as inhibiting activation of the NF-κB signaling pathway (17)(18)(19)(20). Thus, L. plantarum supplementation could be a fascinating strategy for the patients suffering from UC.…”